Clinical trials: Hyperactivity
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03325894
- Testing
- SHP465
- Where
- 48 sites in United States
- Volunteers
- 141 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD
Investigation of efficacy and tolerability of extended-release MPD in adults with ADHD, compared with a placebo, and to acquire knowledge through long-term observation of adults
- Trial name
- EMMA (NCT00619840)
- Testing
- methylphenidate hydrochloride
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Cerebrovascular Accident, Hypercholesterolemia
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
- Trial name
- LA BICHAT (NCT00163150)
- Testing
- Atorvastatin
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
The purpose of this study is to evaluate the effects of videogame-like digital therapy on attentional functioning and symptoms in adolescents ages 13-17 diagnosed with ADHD
- Trial name
- NCT04897074
- Testing
- AKL-T01
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
- Trial name
- NCT00191048
- Testing
- Atomoxetine
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Pediatric Attention Deficit Hyperactivity Disorder
Dasotraline SEP360-105 Pediatric PK/PD Study
Pediatric PK study of SEP-225289 (Dasotraline)
- Trial name
- NCT02195167
- Testing
- Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD.
- Trial name
- NCT02547428
- Testing
- CTN SR
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused.
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00248092
- Testing
- NRP104
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- New River Pharmaceuticals
Healthy Subjects, Attention Deficit
Identification of Biomarkers to Predict Driver Take-over Control Quality
At level 3 conditionally automated, the vehicle ensures driving and the driver disengages from driving to perform another activity independent of driving (ex: read a book, play on his phone ....).
- Trial name
- ANTIDOTE (NCT04188626)
- Testing
- Driving simulator sessions
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PSA Automobiles S.A.
ADHD
Adult Normative Performance of the Quotient ADHD System
This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System…
- Trial name
- ADHD (NCT01308450)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- BioBehavioral Diagnostics Company
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to…
- Trial name
- NCT00343811
- Testing
- Modafinil
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon
ADHD, Narcolepsy
Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
This is a pilot randomized, double-blind, active-controlled, 2-treatment, crossover study to evaluate the PK, user experience and abuse liability of manipulated ADAIR compared to a manipulated commercially-available d-amphetamine…
- Trial name
- NCT04232644
- Testing
- ADAIR 10mg IR capsules, Crushed d-amphetamine sulfate IR tablets
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vallon Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Purpose of the study: evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
- Trial name
- NCT04569357
- Testing
- Prospekta
- Where
- 31 sites in Russia
- Volunteers
- 363 people
- Sponsor
- Materia Medica Holding
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric Extension Study
This is an open label 26 week extension study for subjects who completed SEP360-202.
- Trial name
- NCT02457819
- Testing
- Dasotraline
- Where
- 36 sites in United States
- Volunteers
- 237 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill changes in Korean participants with Attention-Deficit…
- Trial name
- NCT01060150
- Testing
- OROS Methylphenidate HCl
- Volunteers
- 115 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Attention Deficit Disorder With Hyperactivity
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
The purpose of this study is to evaluate the effects of a novel psychological intervention for adult ADHD through a randomized controlled trial.
- Trial name
- NCT04439422
- Testing
- Short ADHD Intervention, Self-help material with limited therapist support
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Cereb AB
ADHD
Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD
This study evaluates the ability to support diagnosis and monitor of the dynamics in ADD/ADHD subjects with an easy to use EEG Device.
- Trial name
- NCT02625805
- Testing
- EEG monitoring (MindWave by NeuroSky), EEG monitoring (EPOC by Emotiv), Methylphenidate
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brainmarc Ltd.
Attention Deficit Hyperactivity Disorder
CX717 in the Treatment of Adult ADHD
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder
- Trial name
- NCT03375021
- Testing
- CX717 200 mg, CX717 800 mg
- Volunteers
- 68 people
- Sponsor
- RespireRx